In a report issued on May 8, Christopher Marai from Nomura maintained a Buy rating on Galapagos (GLPG), with a price target of $290.00. The company’s shares closed last Friday at $217.12.
According to TipRanks.com, Marai is a 4-star analyst with an average return of 3.0% and a 48.8% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Deciphera Pharmaceuticals, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Galapagos is a Moderate Buy with an average price target of $230.40.
See today’s analyst top recommended stocks >>
Based on Galapagos’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $119 million and GAAP net loss of $115 million. In comparison, last year the company earned revenue of $106 million and had a net profit of $14.96 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.